title: Nilotinib versus imatinib: molecular mechanism(s) of its better efficacy.
authors.forename: Rumiana
authors.initials: R
authors.lastname: Bakalova
authors.forename: Zhivko
authors.initials: Z
authors.lastname: Zhelev
authors.forename: Lubomir
authors.initials: L
authors.lastname: Spasov
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D010879:Piperazines; D011743:Pyrimidines; D016044:Fusion Proteins, bcr-abl